Bafna Pharmaceuticals Q1 FY27 Results: Revenue Rs 26 Cr, PAT Rs 0.08 Cr and Key Highlights

Bafna Pharmaceuticals Q1 FY27 results were announced on August 11, 2026, reporting a net profit (PAT) of Rs 0.08 crore, down 97.78% from Rs 3 crore in Q1 FY26. Revenue from operations contracted 23.22% year on year to Rs 26 crore from Rs 34 crore in Q1 FY26. The Bafna Pharmaceuticals Q1 FY27 results are on a standalone basis for the quarter ended June 30, 2026.

Click Here – Get Free Investment Predictions

Bafna Pharmaceuticals Q1 FY27 Financial Highlights

The table below presents key financial metrics from the Bafna Pharmaceuticals Q1 FY27 results against the corresponding quarter of the prior year.

Metric	Q1 FY27 (Jun 2026)	Q1 FY26 (Jun 2025)	YoY Change
Revenue from Operations (Rs Cr)	Rs 26 Cr	Rs 34 Cr	-23.22%
Gross Profit (Rs Cr)	Rs -0.90 Cr	Rs 3 Cr	-124.30%
Net Profit / (Loss) – PAT (Rs Cr)	Rs 0.08 Cr	Rs 3 Cr	-97.78%

Bafna Pharmaceuticals Q1 FY27 Performance Analysis

Use the Univest Screener to Track Live Fundamentals of Indian Stocks

The Bafna Pharmaceuticals Q1 FY27 results show a revenue decline of 23.22% year on year to Rs 26 crore. Gross profit stood at Rs -0.90 crore against Rs 3 crore in Q1 FY26.

Net profit in the June 2026 quarter stood at Rs 0.08 crore, a 97.78% decline year on year. Investors should verify these figures against official BSE and NSE filings.

Key Business Factors in Bafna Pharmaceuticals Q1 FY27

1. Revenue Trend in the June 2026 Quarter

Revenue contracted 23.22% year on year to Rs 26 crore, reflecting near-term headwinds in the Pharmaceuticals segment.

2. Gross Profit and Margin Movement

Gross profit fell to Rs -0.90 crore from Rs 3 crore in Q1 FY26. Higher costs or pricing pressure weighed on gross margins.

3. Net Profit Outcome in Q1 FY27

PAT came in at Rs 0.08 crore, down 97.78% from Rs 3 crore in Q1 FY26. Consistent profitability will depend on revenue and margin trends through FY27.

Dividend Details

No dividend has been declared alongside the Bafna Pharmaceuticals Q1 FY27 results for the quarter ended June 2026. Investors may track any future dividend announcements on BSE and NSE.

Bafna Pharmaceuticals FY27 Outlook After Q1 Results

The June 2026 quarterly results for Bafna Pharmaceuticals present a mixed picture heading into FY27. Gross margin improvement will be critical to strengthening the financial position. Investors tracking Bafna Pharmaceuticals Q1 results should monitor management guidance, sector conditions in Pharmaceuticals, and any strategic developments through the year.

Bafna Pharmaceuticals Stock Performance

Download the Univest iOS App or Univest Android App to track Bafna Pharmaceuticals live share price and upcoming quarterly results.

Bafna Pharmaceuticals share price stood at Rs 273.75 on August 11, 2026, the day the quarterly results were declared. Post-results, the market will assess whether the Pharmaceuticals company's financial performance justifies the current valuation. Investors should verify the latest price and fundamentals on BSE and NSE before any investment decision.

Key Risks to Watch After Bafna Pharmaceuticals Q1 FY27 Results

1. Sector-Specific Demand Headwinds

A slowdown in the Pharmaceuticals sector could weigh on Bafna Pharmaceuticals revenue and profitability beyond what the June 2026 quarter currently indicates.

2. Input Cost and Margin Pressure

Rising raw material or operational costs could compress gross margins and limit net profit improvement in subsequent quarters of FY27.

3. Macroeconomic and Regulatory Uncertainty

Inflation, interest rate movements, and regulatory shifts remain key risks to the Bafna Pharmaceuticals earnings trajectory through FY27.

Conclusion

Bafna Pharmaceuticals Q1 FY27 results report revenue of Rs 26 crore and a net profit (PAT) of Rs 0.08 crore, down 97.78% from Rs 3 crore in Q1 FY26. The June 2026 quarterly performance reflects the company's position in the Pharmaceuticals space. Investors should study the complete financials on BSE and NSE and consult a SEBI-registered advisor before any investment decision.

Frequently Asked Questions on Bafna Pharmaceuticals Q1 FY27 Results

When were the Bafna Pharmaceuticals Q1 FY27 results announced?

Ans. The June 2026 quarterly results for Bafna Pharmaceuticals were announced on August 11, 2026, covering the quarter ended June 30, 2026. The standalone results were filed with BSE and NSE on the same date.

What is the PAT in the Bafna Pharmaceuticals Q1 FY27 results?

Ans. PAT (net profit) stood at Rs 0.08 crore in the June 2026 quarter, down 97.78% from Rs 3 crore in Q1 FY26.

What was the revenue in the Bafna Pharmaceuticals Q1 FY27 results?

Ans. Revenue for the June 2026 quarter fell 23.22% year on year to Rs 26 crore from Rs 34 crore in Q1 FY26.

Did Bafna Pharmaceuticals announce any dividend with the Q1 FY27 results?

Ans. No dividend has been declared alongside the June 2026 quarterly results of Bafna Pharmaceuticals. Investors may track future dividend announcements on the BSE and NSE portals.

What is the Bafna Pharmaceuticals FY27 outlook after Q1 results?

Ans. The June 2026 quarterly data signals a challenging start to FY27 for Bafna Pharmaceuticals. Revenue trends, margin performance, and Pharmaceuticals sector demand will be the key factors to watch through the rest of the financial year.

Is Bafna Pharmaceuticals a good buy after Q1 FY27 results?

Ans. The Q1 FY27 quarterly performance of Bafna Pharmaceuticals reflects challenging trends. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making any investment decision.